Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Fixioneal (a regional brand name or common misspelling of Physioneal) is a peritoneal dialysis (PD) solution used for the treatment of patients with end-stage renal disease (ESRD). It is a bicarbonate/lactate-buffered solution containing glucose as an osmotic agent, along with essential electrolytes including sodium, calcium, magnesium, and chloride. Developed by Baxter, it is designed for use in Continuous Ambulatory Peritoneal Dialysis (CAPD) or Automated Peritoneal Dialysis (APD). The solution is formulated to be more biocompatible than traditional acidic, glucose-based PD solutions by maintaining a physiological pH (approximately 7.4) and reducing the formation of glucose degradation products (GDPs), which helps preserve the peritoneal membrane's function over long-term therapy. It is typically available in different buffer strengths, such as 35 mmol/L or 40 mmol/L, to tailor treatment to the patient's acid-base status.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on physioneal (Baxter International Inc.).